It's close on 2 1/2 years since this was announced and us USians find ourselves left with a choice of Medtronic CGMs (which are effectively tied to Medtronic pumps) or Dexcom CGMs.
That's not a lot of choice.
At the time Abbott blamed "supply" problems (see the previous 2011 posts) but it is inconceivable that supply, or manufacturing, problems will hold a product back in one of the worlds major markets when that same product continues to be manufactured and supplied in the other major markets.
Elsewhere (http://integrateddiabetes.com/Articles/cgm/cgm%20comparisons%20for%20diatribe.pdf [diatribe]) "cost/reimbursement" problems were blamed. But this year the whole cost/reimbursement scene in the US changed with the introduction of many more insurance companies to the diabetic market. (I.e. insurance companies that, prior to Jan 1 2014, simply didn't cover diabetics.)
And in other places it is suggested that there were licensing issues with the original developer of the sensor Abbott was using.
Meanwhile it is clear that Abbott continues to market the FreeStyle Navigator II everywhere but the US and that the price is comparable with the Dexcom G4.
Does anyone have any idea about what is going on?